Abstracts tagged "axial spondyloarthritis"

Abstract Number: 1867 • 2018 ACR/ARHP Annual Meeting
Drug Retention and Response Rates of TNFi Treatment in 21,470 Patients with Axial Spondyloarthritis Treated in Clinical Practice– Pooled Data from the Eurospa Research Network Collaboration
Cecilie Heegaard Brahe¹, Lykke Midtbøll Ørnbjerg¹, Johan Askling², Adrian Ciurea³, Eirik K Kristianslund⁴, Fatos Onen⁵, Dan Nordström⁶, Maria José Santos⁷, Catalin Codreanu⁸, Ziga Rotar⁹, Björn Gudbjornsson¹⁰, Daniela Di Giuseppe², Michael J. Nissen¹¹, Tore Kvien⁴, Merih Birlik⁵, Nina Trokovic⁶, Anabela Barcelos⁷, Ruxandra Ionescu⁸, Matija Tomšič⁹, Arni Jon Geirsson¹⁰, Anne Gitte Loft¹, Herman F Mann¹², Tamara Rusman¹³, Juan J. Gomez-Reino¹⁴, Gareth T. Jones¹⁵, Florenzo Iannone¹⁶, Karel Pavelka¹², Irene van der Horst-Bruinsma¹⁷, Lise Hyldstrup¹, Niels Steen Krogh¹⁸, Merete Lund Hetland¹ and Mikkel Østergaard¹, ¹DANBIO, EuroSpA Research Collaboration Network, Coordinating Centre, Copenhagen, Denmark, ²ARTIS, EuroSpA Research Collaboration Network, Stockholm, Sweden, ³SCQM, EuroSpA Research Collaboration Network, Zurich, Switzerland, ⁴NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁵TURKBIO, EuroSpA Research Collaboration Network, Izmir, Turkey, ⁶ROB-FIN, EuroSpA Research Collaboration Network, Helsinki, Finland, ⁷Reuma.pt, EuroSpA Research Collaboration Network, Lisbon, Portugal, ⁸RRBR, EuroSpA Research Collaboration Network, Bucharest, Romania, ⁹biorx.si, EuroSpA Research Collaboration Network, Ljubljana, Slovenia, ¹⁰ICEBIO, EuroSpA Research Collaboration Network, Reykjavik, Iceland, ¹¹SCQM, EuroSpA Research Collaboration Network, Geneva, Switzerland, ¹²ATTRA, EuroSpA Research Collaboration Network, Prague, Czech Republic, ¹³ARC, EuroSpA Research Collaboration Network, Haarlem, Netherlands, ¹⁴BIOBADASER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁵BSRBR-AS, EuroSpA Research Collaboration Network, Aberdeen, United Kingdom, ¹⁶GISEA, EuroSpA Research Collaboration Network, Bari, Italy, ¹⁷ARC, EuroSpA Research Collaboration Network, Harleem, Netherlands, ¹⁸Zitelab, EuroSpA Research Collaboration Network, Copenhagen, Denmark
Drug retention and response rates of TNFi treatment in 21,470 patients with axial spondyloarthritis treated in clinical practice– pooled data from the EuroSpA Research Network…
Abstract Number: 675 • 2018 ACR/ARHP Annual Meeting
Quantitative Ultrasound of the Calcaneus Has a Role to Play in Detecting Low Bone Mineral Density in Axial Spondyloarthropathy Patients
Gillian Fitzgerald^1,2, Tochukwu Anachebe³, Ronan Mullan⁴, David Kane⁵, Kevin McCarroll⁶ and Finbar O' Shea², ¹School of Medicine, Trinity College Dublin, Dublin 2, Ireland, ²Rheumatology, St. James's Hospital, Dublin 8, Ireland, ³Department of Rheumatology, St. James's Hospital, Dublin 8, Ireland, ⁴Department of Rheumatology,, Tallaght Hospital, Dublin, Ireland, ⁵Department of Rheumatology, Tallaght Hospital, Dublin 24, Ireland, ⁶Department of Medicine for the Elderly, St. James's Hospital, Dublin 8, Ireland
Background/Purpose: Axial spondyloarthropathy (axSpA) patients have an increased risk of developing osteoporosis compared to matched controls. Dual energy x-ray absorptiometry (DXA) is the technique of…
Abstract Number: 1868 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety Outcomes in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the First 52-Week Randomized Placebo-Controlled Study (NCT02552212)
Atul A. Deodhar¹, Lianne S. Gensler², Jonathan Kay³, Walter P. Maksymowych⁴, Nigil Haroon⁵, Robert B.M. Landewé⁶, Martin Rudwaleit⁷, Stephen Hall⁸, Lars Bauer⁹, Bengt Hoepken⁹, Natasha de Peyrecave¹⁰, Brian Kilgallen¹¹ and Désirée van der Heijde¹², ¹Oregon Health and Science University, Portland, OR, ²University of California San Francisco, San Francisco, CA, ³Division of Rheumatology, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester, MA, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Amsterdam Rheumatology & Clinical Immunology Center and Zuyderland Medical Center, Amsterdam; Heerlen, Netherlands, ⁷Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Bielefeld, Germany, ⁸Cabrini Medical Centre, Cabrini Private Hospital, Malvern, Australia, ⁹UCB Pharma, Monheim, Germany, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Raleigh, NC, ¹²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the USA, certolizumab pegol (CZP) is approved for treatment of adults with active ankylosing spondylitis (AS) and not for non-radiographic axial spondyloarthritis (nr-axSpA).…
Abstract Number: 2500 • 2017 ACR/ARHP Annual Meeting
Are Work Outcomes Improved in Axial Spondyloarthritis (axSpA) Patients with Biologic Therapy? Results from the British Society for Rheumatology Register
Gary J. Macfarlane, Gareth T. Jones and Joanna Shim, Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom
Background/Purpose: Patients with axial spondyloarthritis (axSpA) identify the ability to stay at work as a priority. Biologic therapy improves disease activity and quality of life…
Abstract Number: 2501 • 2017 ACR/ARHP Annual Meeting
Potential Differences in Axial Spondyloarthritis Disease Activity Categorization Using Different Minimum Values for High-Sensitivity CRP in Ankylosing Spondylitis Disease Activity Score Calculation and Different Definitions of Disease Flare
Robert B.M. Landewé¹, Joachim Sieper², Uta Kiltz³, Xin Wang⁴, Mei Li⁴ and Jaclyn K. Anderson⁴, ¹University of Amsterdam, Amsterdam, Netherlands, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: It has been recommended that the lower limit of high-sensitivity CRP (hsCRP) be restricted to 2 in the Ankylosing Spondylitis Disease Activity Score (ASDAS)…
Abstract Number: 581 • 2017 ACR/ARHP Annual Meeting
Diagnostic Value of Anti-CD74 Antibodies in Early Axial Spondyloarthritis: Data from the Spondyloarthritis Caught Early (SPACE) Cohort
Janneke de Winter¹, Marleen van de Sande¹, Niklas Thomas Baerlecken², Inger Berg³, Roberta Ramonda⁴, Désirée van der Heijde⁵, Floris van Gaalen⁶, Torsten Witte⁷ and Dominique Baeten^1,8, ¹Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, Private Practice, Cologne, Germany, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ⁸UCB Pharma, Slough, United Kingdom
Background/Purpose: Anti-CD74 IgG antibodies are reported to be elevated in serum of patients with axial spondyloarthritis (axSpA). This study aimed to assess the diagnostic value…
Abstract Number: 2504 • 2017 ACR/ARHP Annual Meeting
The Validation of Istanbul Back Disability Index (IBDI) in Axial Spondyloarthritis Patients
Tuncay Duruoz, Hatice Sule Baklacioglu, Sevtap Acer Kasman and Didem Erdem, PMR Department, Rheumatology Division, Marmara University School of Medicine, Istanbul, Turkey
Background/Purpose: The IBDI was developed to assess the disability in patients with mechanical low back pain (1) which contains the 18 daily activities questions. The…
Abstract Number: 584 • 2017 ACR/ARHP Annual Meeting
Factors Associated with the “Bamboo Spine” Phenotype – Data from the Comospa Study
Koei Oh¹, Anna Molto², Corinne Miceli-Richard³, Soksay Singvongsa⁴, Adrien Etcheto⁴ and Maxime Dougados⁴, ¹Departmen of Rheumatology, Paris Descartes University, Hôpital Cochin, Paris, France, ²Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ³Department of Rheumatolgy, Paris Descartes University, Hôpital Cochin, Paris, France, ⁴Department of Rheumatology, Paris Descartes University, Hôpital Cochin, Paris, France
Background/Purpose: The factors associated with “Bamboo spine” occurrence, i.e. the most severe axial phenotype of SpA patients, have been poorly assessed to date. The aim…
Abstract Number: 2514 • 2017 ACR/ARHP Annual Meeting
When Should Lateral Dexa be Used to Measure Spine Bone Mineral Density in Axial Spondyloarthritis Patients: A Cross-Sectional Study
Sizheng Zhao^1,2, Daniel Thong³, Eleanor Quilliam², Stephen Duffield¹, Kai-Wei Yin³ and Nicola Goodson^1,2, ¹Musculoskeletal Biology 1 Department, University of Liverpool, Liverpool, United Kingdom, ²Aintree University Hospital, Liverpool, United Kingdom, ³University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Osteoporosis and vertebral fractures are recognized complications in axial spondyloarthritis (axSpA). Anteroposterior (AP) DEXA is commonly used to assess spinal bone mineral density (BMD)…
Abstract Number: 644 • 2017 ACR/ARHP Annual Meeting
Association of Osteonectin, Osteopontin and Osteocalcin with Inflammation and Cardiovascular Risk in Patients with Axial Spondyloarthritis
Fernanda Genre¹, Javier Rueda-Gotor², Juan Irure-Ventura³, Sara Remuzgo-Martínez¹, Alfonso Corrales¹, Begoña Ubilla¹, Veronica Mijares¹, Carlos Fernández-Díaz¹, Virginia Portilla¹, Ricardo Blanco¹, Javier Llorca⁴, J. Gonzalo Ocejo-Vinyals³, Raquel López-Mejías¹ and Miguel Angel González-Gay⁵, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Immunology Division, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL and School of Medicine, University of Cantabria, Santander, Spain
Background/Purpose: A higher incidence of cardiovascular (CV) risk factors and atherosclerosis has been reported in axial spondyloarthritis (axSpA) patients1. Since axSpA (particularly AS) is an…
Abstract Number: 2516 • 2017 ACR/ARHP Annual Meeting
Trabecular Bone Score As an Assessment Tool to Identify the Risk of Osteoporosis in Axial Spondyloarthritis: A Case-Control Study
Kwi Young Kang, Internal Medicine, Catholic University of Korea, Seoul, Korea, Republic of (South)
Background/Purpose: The trabecular bone score (TBS) is a novel tool used to evaluate bone microarchitecture. It is a textural index that evaluates pixel gray-level variations…
Abstract Number: 1315 • 2017 ACR/ARHP Annual Meeting
Influence of Rheumatoid Arthritis and Axial Spondyloarthritis on Pregnancy Complications, Pregnancy Outcome and Delivery Mode
Frauke Förger¹, Stephanie van den Brandt², Astrid Zbinden³, Monika Ostensen³ and Peter M. Villiger³, ¹Inselspital, University of Bern, Bern, Switzerland, ²Clinical Immunology and Rheumatology, University of Amsterdam, Amsterdam, Netherlands, ³Rheumatology, Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland
Background/Purpose: To analyze pregnancy complications, pregnancy outcome and delivery mode in patients with rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA).Methods: Patients with RA and axSpA…
Abstract Number: 2521 • 2017 ACR/ARHP Annual Meeting
Metabolic Syndrome Is Associated with Active Disease in Psoriatic Arthritis and May Contribute to Development of Syndesmophytes
Pervin Sanci¹, Gokce Kenar², Berrin Zengin², Sadettin Uslu³, Aydan Koken³, Handan Yarkan³, Gerçek Can³, Merih Birlik³ and Fatos Onen², ¹Internal Medicine, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ³Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey
Background/Purpose: An increased prevalence of metabolic syndrome (MetS) has been reported in psoriatic arthritis (PsA) suggesting an association between the inflammation and MetS. The aim…
Abstract Number: 1503 • 2017 ACR/ARHP Annual Meeting
The Prevalence of Axial Spondyloarthritis in Israel
Sara Borok Lev-Ran¹, Hagit Sarvagyl-Maman², Victoria Furer³, Sara Pel⁴, Iddo Drukman⁵, Gideon Flusser⁵ and Ori Elkayam⁶, ¹Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine,Tel Aviv University, Tel AViv, Israel, ²Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-aviv, Israel, ³Rheumatology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁴Rheumatology, Sourasky Medical Center, Tel Aviv, Israel, ⁵Radiology, Tel Aviv Medical Center, Tel Aviv, Israel, ⁶Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Background/Purpose: The concept of axial Spondyloarthritis (SpA) as defined by the ASAS criteria is relatively new. While the prevalence of Ankylosing spondylitis is around 0.5%,…
Abstract Number: 2803 • 2017 ACR/ARHP Annual Meeting
Predictors of Remission Maintenance up to Week 68 and Successful Therapy Discontinuation in Patients with Non-Radiographic Axial Spondyloarthritis Who Achieved Sustained Remission on 28-Week Open-Label Adalimumab Treatment
Joachim Sieper¹, Robert B.M. Landewé², Marina N. Magrey³, Jaclyn K. Anderson⁴, Sheng Zhong⁴, Xin Wang⁴ and Apinya Lertratanakul⁴, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²University of Amsterdam, Amsterdam, Netherlands, ³Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, OH, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Sustained remission is an important treatment goal in patients (pts) with non-radiographic axial SpA (nr-axSpA). Factors predicting successful remission maintenance are unknown. We sought…

« Previous Page
1
…
8
9
10
11
12
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.